492 related articles for article (PubMed ID: 15583642)
1. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
2. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
3. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
4. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
5. The drive to reform the FDA gains momentum.
Gatty B
Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
[No Abstract] [Full Text] [Related]
6. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
7. Trials and error.
Jacobs T
Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
[No Abstract] [Full Text] [Related]
8. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
9. Getting SMART (submission management and review tracking) drug review in the computer age.
Flieger K
FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
[TBL] [Abstract][Full Text] [Related]
10. BIO and biogenerics.
Feldbaum CB
Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
[No Abstract] [Full Text] [Related]
11. What ails the FDA?
Jenny-Avital ER
N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
[No Abstract] [Full Text] [Related]
12. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
Lee VH
Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
[No Abstract] [Full Text] [Related]
13. 8 keys to compliance for Medical Science Liaisons.
Werling K; Heinze G
Health Care Law Mon; 2007 Apr; ():3-6. PubMed ID: 17476734
[No Abstract] [Full Text] [Related]
14. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
Milton MN; Horvath CJ
Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
[No Abstract] [Full Text] [Related]
15. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
16. Regulators scramble to tighten loopholes after heparin debacle.
Jia H
Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
[No Abstract] [Full Text] [Related]
17. Who would approve new drugs if there were no FDA?
Gatty B
Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
[No Abstract] [Full Text] [Related]
18. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
19. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
20. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
[Next] [New Search]
